Canada Post Corp Registered Pension Plan Grows Stock Holdings in Boston Scientific Corporation $BSX

Canada Post Corp Registered Pension Plan raised its stake in Boston Scientific Corporation (NYSE:BSX) by 17.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 54,197 shares of the medical equipment provider’s stock after buying an additional 7,960 shares during the period. Canada Post Corp Registered Pension Plan’s holdings in Boston Scientific were worth $5,259,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of BSX. State Street Corp boosted its stake in shares of Boston Scientific by 1.1% during the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after purchasing an additional 713,379 shares during the last quarter. Synergy Asset Management LLC boosted its position in Boston Scientific by 3,493.0% during the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock worth $48,297,000 after acquiring an additional 479,593 shares during the last quarter. Gladstone Institutional Advisory LLC boosted its position in Boston Scientific by 39.5% during the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock worth $5,065,000 after acquiring an additional 14,700 shares during the last quarter. Channel Wealth LLC grew its stake in Boston Scientific by 70.8% in the 3rd quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock worth $2,790,000 after acquiring an additional 11,847 shares during the period. Finally, Bank of Nova Scotia raised its holdings in Boston Scientific by 106.4% in the 2nd quarter. Bank of Nova Scotia now owns 3,025,519 shares of the medical equipment provider’s stock valued at $324,971,000 after acquiring an additional 1,559,605 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat but mixed outlook — Boston Scientific reported stronger-than-expected Q4 results (revenue growth and EPS beat), showing continued top-line momentum that supports the longer‑term growth story. Q4 results and presentation
• Positive Sentiment: Some analysts still rate BSX as a buy/overweight with mid‑to‑high price targets — several firms left positive ratings (Morgan Stanley set a $118 PT; others keep “outperform/overweight”), indicating continued analyst confidence in long-term upside despite near-term caution. Morgan Stanley PT note
• Neutral Sentiment: Board change announced — Boston Scientific disclosed a planned long‑serving director departure; governance turnover is notable but not currently flagged as material to near‑term operations. Board director departure
• Neutral Sentiment: Unusually active options and volume — options and share volume spiked during the sell‑off, increasing volatility and making short-term price moves more extreme (can amplify both down and up moves). Options activity
• Negative Sentiment: Cautious 2026 guidance and weak electrophysiology sales drove a sharp sell‑off — management’s conservative revenue/growth guidance and softer performance in a key segment prompted a high‑volume liquidation that erased recent gains. Guidance and segment weakness
• Negative Sentiment: Multiple securities‑fraud investigations announced — several law firms have opened inquiries into Boston Scientific’s disclosures around the quarter/guidance, increasing legal and reputational risk. Howard G. Smith investigation Frank R. Cruz investigation
• Negative Sentiment: Insider selling and new lows — CEO share sales and headlines about insider selling coincided with the stock reaching a 12‑month low, which can undermine investor confidence even when fundamentals are mixed. CEO stock sale note 12-month low report
• Negative Sentiment: Widespread analyst price‑target cuts — multiple firms trimmed their 12‑month targets after Q4/guidance, increasing short‑term downside pressure even where ratings remain constructive. Analyst cuts roundup

Boston Scientific Stock Down 1.8%

BSX opened at $76.24 on Friday. The firm has a 50 day moving average price of $93.39 and a 200 day moving average price of $98.79. The company has a market cap of $113.02 billion, a PE ratio of 39.30, a price-to-earnings-growth ratio of 1.37 and a beta of 0.67. Boston Scientific Corporation has a 1 year low of $74.86 and a 1 year high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same period in the previous year, the company posted $0.70 earnings per share. Boston Scientific’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on BSX shares. Citigroup decreased their price objective on Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a report on Thursday. Evercore decreased their price target on Boston Scientific from $112.00 to $96.00 and set an “outperform” rating on the stock in a research note on Thursday. UBS Group dropped their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a research note on Thursday. Mizuho cut their price objective on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Truist Financial lowered their target price on shares of Boston Scientific from $120.00 to $95.00 and set a “buy” rating for the company in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.43.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is currently owned by corporate insiders.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.